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111Acute myocardial infarction (MI) results in the replacement
of living heart muscle by a ﬁbrous scar. Although traditional
therapeutic strategies (timely reperfusion and optimal drug-
and device-based therapies) have reduced MI-associated
mortality (1), new approaches are needed for patients in
whom left ventricular (LV) dysfunction develops (2). To that
end, over the past decade, cell therapy has emerged as a
promising treatment strategy. Multiple cell types including
bone marrow mononuclear cells (3–6), bone marrow
mesenchymal cells (7), and adipose tissue–derived cells (8)
have been used in the setting of acute or convalescent MI,
but efﬁcacy has been inconsistent (3–6) and, overall, modest
(9). Six-month primary endpoint analysis of the proof-of-
concept, prospective, randomized, controlled CADUCEUS
(CArdiosphere-Derived aUtologous stem CElls to reverse
ventricUlar dySfunction) trial (10) demonstrated the
feasibility of harvesting, expanding, and delivering autolo-
gous CDCs (11) by intracoronary infusion in post-MI
patients. We found that autologous CDCs appear to be
safe and effective in decreasing scar size, increasing viable
myocardium, and improving regional myocardial function at 6
months post-treatment. However, whether these effects
are sustained at 1 year after cell administration is unknown.
Here, we report the ﬁnal 1-year endpoint results of the
CADUCEUS trial, including a comprehensive magnetic
resonance imaging (MRI) analysis of myocardial regeneration
and clinical correlates of regenerative efﬁcacy.SAE = serious adverse
event(s)
TnI = troponin I
VO2 = oxygen consumptionMethods
The CADUCEUS study design. The detailed study
protocol, complete 6-month (including the primary safety
endpoint) and partial 1-year follow-up results of the
CADUCEUS trial were reported previously (10,12). In
brief, 31 eligible participants with a recent reperfused MI
(4 weeks previously) and moderate LV dysfunction (ejec-
tion fraction [EF] 25% to 45% by clinically indicated post-
MI imaging) were randomly allocated in a 2:1 ratio at 2
medical centers in the United States (Cedars-Sinai Medical
Center and The Johns Hopkins Hospital) to receive autol-
ogous CDCs and standard care or standard care alone.
Patients randomized to receive CDCs underwent endo-
myocardial biopsy to harvest tissue for autologous cell
production. When the pre-speciﬁed dose was achieved,
patients returned for cell infusion using a stop-ﬂow tech-
nique via an over-the-wire balloon angioplasty catheter,
positioned in the infarct-related coronary artery at the site of
the previously implanted stent. One patient petitioned to
undergo late treatment and was infused 14 months post-MI,
after a protocol exception was approved by the U.S. Food
and Drug Administration and by the Cedars-Sinai institu-
tional review board.
Patientswere followed 2weeks and1, 2, 3, 6, and 12months
after CDC infusion or at corresponding comparable times
post-MI for control patients. Patients underwent 48-h
ambulatory electrocardiographic monitoring at each studyvisit. Adverse events were inde-
pendently monitored by a physi-
cian at the Data Coordinating
Center (EMMES Corporation,
Rockville, Maryland) and by the
National Heart, Lung, and Blood
Institute Gene and Cell Therapy
Data and Safety Monitoring
Board (DSMB). Efﬁcacy was
assessed by the New York Heart
Association (NYHA) functional
class, the Minnesota Living With
Heart Failure Questionnaire (13),
the 6-minwalk test (6MWT), peak
oxygen consumption (VO2), and
MRI. Contrast-enhanced cardiac
MRI studies were performed at
baseline and at 6 and 12 months.
CardiacMRI in the CADUCEUS
trial. Cardiac MRI was per-
formed to measure LV scar mass,
LV viable myocardial mass (i.e.,
total LV mass minus LV scar
mass), scar size (LV scar mass
divided by total LV mass), LV
volumes, global function, and
regional function. MRI was
performed using 1.5-T magnets
(Avanto, Siemens Medical
Solutions, Erlangen, Germany).
Global LV function, regional
systolic thickening, and regional end-systolic thickness were
assessed using a true fast imaging steady-state free-preces-
sion pulse sequence (TrueFISP) with breath-holding
acquisitions (14). LV endo- and epicardial borders,
deﬁned in the end-diastolic and end-systolic frame in
contiguous slices, were used to calculate LV parameters (LV
end-diastolic and end-systolic volumes, LV mass, EF) as
described (15), using U.S. Food and Drug Administration–
approved software (QMass MR, Medis Medical Imaging
Systems, Leiden, the Netherlands). To measure regional
systolic thickening and end-systolic thickness in infarcted
myocardial segments, each cardiac short-axis slice was
divided into 6 segments, using the right ventricular insertion
as a reference point. Infarcted myocardial segments were
visually identiﬁed from matched delayed contrast-enhanced
images, and systolic thickening and end-systolic thickness
were calculated for each infarcted segment (QMass MR,
Medis Medical Imaging Systems). To assess circumferential
strain, cardiac magnetic resonance tagged images were
acquired with an electrocardiographically gated, segmented
K-space, fast gradient-recalled-echo pulse sequence with
spatial modulation of magnetization to generate a grid-
tagged pattern (16). Tagged images were quantitatively
analyzed using a custom software package (Diagnosoft
HARP, Diagnosoft Inc., Palo Alto, California), as described
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112previously (17). The peak systolic circumferential strain
(Ecc), determined from the strain map of each point, was
assessed in infarcted segments. The American Heart As-
sociation 16-segment model (18) was used, and in-
farcted segments were visually identiﬁed (from delayed
contrast-enhanced images) in 3 short-axis slices (1 basal
slice, 1 mid-ventricular, and 1 apical slice for each patient).
Mid-wall Ecc, a measure of regional contractility calculated
from tagged cardiac magnetic resonance images (19), was
assessed in each infarcted segment. Approximately 15 min
after intravenous delivery of gadolinium diethylenetriamine
pentaacetic acid contrast (0.2 mmol/kg body weight, Mag-
nevist, Berlex, Wayne, New Jersey), delayed contrast-
enhanced images were acquired to assess scar size with an
electrocardiographically gated, breath-hold, interleaved,
inversion recovery, 2-dimensional TurboFLASH sequence
(20). Scar size from delayed contrast-enhanced cardiac MRI
was deﬁned based on the full width at half maximum
(FWHM) criterion (21), which uses pixels with >50% of
the maximal signal intensity to delineate scarred myocar-
dium. For the parameters speciﬁed above, images were
analyzed in the core laboratory at The Johns Hopkins
University by an experienced observer blinded to treatment
groups (QMass MR, Medis Medical Imaging Systems).
Delayed contrast-enhanced images obtained from 2 CDC-
treated patients were deemed technically uninterpretable by
the imaging core laboratory and were excluded from analysis.
Additional comprehensive analysis of myocardial regenera-
tion was carried out by a reader at the Cedars-Sinai Heart
Institute (K.M.), using the infarct contours determined by
The Johns Hopkins University imaging core laboratory.
Delayed contrast-enhanced images and their corresponding
cine short-axis cardiac images were matched across time
points (baseline and 1 year). Each cardiac slice was divided
into 6 segments (using the right ventricular insertion as
a reference point), infarcted segments were visually identiﬁed
from delayed contrast-enhanced images, and scar size and
systolic thickening were calculated for each individual
infarcted segment at baseline and 1 year.
Three patients received implantable cardioverter-deﬁbrillators
(ICDs) due to clinical indications (low EF) during the
course of the study; a contraindication to MRI developed in
these patients, and therefore they underwent cardiac
computed tomography (CT) instead. Two patients had
ICDs implanted between the 6-month and 1-year visits; as
a result, these patients underwent MRI at screening, base-
line, and 6 months and CT imaging at 1 year. One patient
had the ICD implanted between screening and baseline; as
a result, this patient underwent MRI at screening and CT at
baseline, 6 months, and 1 year. Validation studies comparing
MRI with CT have shown that, although changes in scar
size, global function, and volumes are comparable when the
same modality (either MRI or CT) is used across time
points, CT and MRI values cannot be used interchangeably
(especially for infarct size measurements) (15); we therefore
chose not to mix different imaging modalities in the presentanalyses. Thus, within-patient treatment effects presented in
the main paper were calculated only for data collected with
matching modalities; MRI was used in all cases except for
the single study patient who underwent CT at baseline,
6 months, and 1 year. The results from this patient were
representative of CDC-treated patients; omission of the
imaging data from that patient did not inﬂuence any of the
conclusions. For the sake of inclusiveness, all collected
measurements are presented in the Online Appendix,
regardless of whether data were obtained with matching
(MRI-MRI, CT-CT) or nonmatching (MRI-CT) imaging
modalities at different time points; however, the non-
matching data should be interpreted cautiously given the
intrinsic differences between MRI and CT as means of
quantifying scar (15).
Based on the above, the within-patient treatment
effects of EF, EDV, ESV, cardiac output, stroke volume,
and LV mass (between baseline and 1 year) presen-
ted in the paper come from 14 CDC-treated patients
(17 patients minus 1 who was lost to follow-up and 2
who were switched from MRI to CT and thus did not
have data from matching imaging modalities) and 7
control patients (8 control patients, 1 of whom was lost to
follow-up). The absolute values of EF, EDV, ESV,
cardiac output, stroke volume, and LV mass presented in
the paper come from 13 CDC-treated patients (as we
chose not mix absolute values obtained from MRI and
CT, and thus we excluded the 1 patient who underwent
CT at baseline and 1 year) and 7 control patients. The
within-patient treatment effects of scar size, scar mass,
and viable mass (between baseline and 1 year) presented
in the paper come from 12 CDC-treated patients
(as these parameters are calculated from delayed contrast-
enhanced images and delayed contrast-enhanced images
obtained from 2 CDC-treated patients were deemed
technically uninterpretable by the imaging core labora-
tory) and 7 control patients. The absolute values of scar
size, scar mass, and viable mass presented in the paper
come from 11 CDC-treated patients (as we chose not to
mix absolute values obtained from MRI and CT, and
thus we excluded the 1 patient who underwent CT at
baseline and 1 year) and 7 control patients.
Relationship between scar size and EF in convalescent
MI patients. To investigate the relationship between scar
size and EF in convalescent MI patients, 90 patients
underwent cardiac MRI w5 months after MI (days from
MI to MRI: 156  107) at Northwestern Memorial
Hospital. Cardiac MRI was performed using a 1.5-T clinical
scanner (Sonata or Avanto, Siemens). All images were
acquired during repeated breath-holds and were electrocar-
diographically gated (22). Global LV function was assessed
using a cine steady-state free-precession sequence. Delayed
contrast-enhanced images were acquired to assess scar size
10 min after the intravenous delivery of gadolinium contrast
(0.2 mmol/kg body weight) using a T1-weighted, inver-
sion recovery, fast gradient-echo pulse sequence (20). Left
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113ventricular ejection fraction (LVEF) and scar size were
measured by a blinded expert observer as described (22).
Statistics. Results are presented as mean  SD in the text
and tables and as mean  SEM in the ﬁgures. Categorical
data were tested using Fisher’s exact test. For continuous
measures, normality of data in each group was tested
using the Shapiro-Wilk test. If normality was establi-
shed, differences between 2 groups (control patients and
CDC-treated patients) were tested using an independent-
sample Student t test. If normality could not be estab-
lished, differences between the 2 groups were tested using
the nonparametric Mann-Whitney U test. Comparisons of
changes from baseline within groups were performed using
a paired Student t test (if normality was established) or the
nonparametric Wilcoxon test (if normality could not be
established). Repeated-measures analyses (when >2 time
points were included in the analysis [troponin I (TnI)] and
creatine kinase-myocardial band [CK-MB]) were per-
formed using the Friedman test; post-hoc analysis was
conducted with the Wilcoxon signed rank test with Bon-
ferroni correction (to adjust for multiple comparisons). To
investigate predictors of regenerative efﬁcacy, bivariate
Pearson’s correlation and multiple linear regression anal-
yses were performed. It should be noted that there is no
reasonable expectation of a linear correlation between
parameters, but the regressions are presented to indicate
trends other than zero. No multiplicity adjustment for
multiple efﬁcacy endpoints was performed because these
endpoints were exploratory and hypothesis generating. All
tests were 2 sided, and a p value < 0.05 was considered
statistically signiﬁcant. The results of the Shapiro-Wilk
test, the test used for between-groups or within-group
comparisons, and the calculated p values for all statistical
comparisons included in the paper are listed in the Online
Appendix.Results
Patient population and CDC characteristics. A total of
31 patients were randomized (23 to the CDC group and 8
to the control group). Of the 23 patients allocated to the
CDC group, 2 withdrew consent before biopsy specimen
procurement, 1 became ineligible for infusion due to an
occlusion of the infarct-related artery detected incidentally at
the time of intended infusion, and there were 3 technical
manufacturing failures (for details, see elsewhere [10]).
Thus, the ﬁnal patient population consisted of 17 CDC-
treated patients and 8 control patients. Four patients
received a low dose of 12.5 million CDCs, 12 received
a higher dose of 25M CDCs (deﬁned as the maximal safe
dose in pre-clinical studies [23]) and 1 received an inter-
mediate dose of CDCs (17.3 million) to ﬁt within the
protocol-speciﬁed constraint of the delivery window (no
longer than 90 days post-MI). The required CDC dose was
achieved at an average of 36  6 days after biopsy
procurement and 65  14 days post-MI. Two patients(1 treated and 1 control) were lost to follow-up and did not
complete their 1 year visits. One patient, who was
randomized to the CDC group underwent biopsy but did
not receive CDCs due to a technical manufacturing failure,
completed all follow-up studies during the ﬁrst year
(including cardiac MRI) and subsequently underwent
a repeat biopsy and infusion off-protocol 14 months post-
MI. This patient was followed for 1 additional year post-
CDC infusion and underwent additional cardiac MRI
studies at 6 months and 1 year post-CDC infusion (20 and
26 months post-MI, respectively).
There were no signiﬁcant differences in baseline charac-
teristics between groups (a detailed list of baseline charac-
teristics is available elsewhere [10]). The left anterior
descending coronary artery (or its diagonal branch) was the
culprit vessel of the index MI in 92% of the patients. The
average LVEF at baseline was 39  12%, the average scar
size equaled 24  10%, and 74% of patients were NYHA
functional class I.
Consistent with previous characterizations (11,24), ﬂow
cytometry revealed that CDCs are cells of nonhematological
origin (CD45) that are uniformly positive for CD105;
25.1% of CDCs were positive for CD90 (a marker of
mesenchymal cells [25,26] or ﬁbroblasts [27]), 2.9% were
positive for c-Kit (associated with a subtype of cardiac
progenitors [28]), whereas <4% of CDCs were positive for
ﬁbroblast (discoidin domain-containing receptor 2 [29]),
myoﬁbroblast (a-smooth muscle actin [30]), smooth muscle
cell (a-smooth muscle actin), or endothelial cell (CD31)
markers (31) (Fig. 1).
Safety. No serious adverse events (SAEs) were associated
with biopsy procurement. CDCs are known to be large
relative to capillaries (w20-mm vs. w8-mm diameter), so
that microvascular occlusion is expected as the dose escalates
(23,32). We thus looked carefully for any evidence of clin-
ically signiﬁcant infusion-related MI or of subclinical
increases in ischemic biomarkers in CDC-treated patients.
On average, TnI (but not CK-MB) increased signiﬁcantly,
from a mean of 0.048 ng/ml to a peak of 0.157 ng/ml
at 24 h, with full resolution at 14 days (0.044 ng/ml)
(p < 0.001). Among individual patients, 15 had no increase
in TnI (as ruled by the DSMB), whereas 2 experienced mild
discrete elevations judged to be related to treatment. An
additional patient experienced ST-segment elevations with
chest pain during the balloon occlusion for infusion, which
resolved fully afterward, without changes in TnI. A complete
list of the acquired TnI and CK-MB data for each CDC-
treated patient is provided in Online Table 1.
Within 12 months of infusion, SAEs (classiﬁed according
to MedDRA) were noted in 7 patients: 6 of 17 (35.3%)
CDC-treated and 1 of 8 (12.5%) control patients (p ¼ 0.36).
The 8 episodes of SAEs experienced in the CDC group by 12
months included acute MI (n ¼ 1), chest pain (n ¼ 2),
coronary revascularization (n ¼ 1), ICD insertion (n ¼ 1),
and other 3 noncardiac events (dyspepsia, anxiety, alcohol
poisoning). Two of the 8 SAEs (chest pain and ICD
Table 1 Adverse Events in CDC-Treated and Control Patients
CDCs Controls p Value
Serious adverse events 6/17 1/8 0.36
Hospitalizations 6/17 1/8 0.36
Nonsustained ventricular tachycardia 8/17 2/8 0.40
Sustained ventricular
tachycardia/ventricular ﬁbrillation
0/17 0/8 1.0
Death/MACE/tumor 1/17 0/8 1.0
CDC ¼ cardiosphere-derived cell; MACE ¼ major adverse cardiac event(s).
Figure 1 CDC Manufacturing and Phenotypic Characterization
(A) Biopsy specimens are minced into w1 mm3 explants. Explants are plated and spontaneously yield outgrowth cells (left). Outgrowth cells are harvested and plated in
suspension culture, where they self-assemble into cardiospheres (middle). Cardiospheres are subsequently replated in ﬁbronectin-coated dishes to yield CDCs (right). (B)
Representative ﬂow cytometry histograms for CD105 and CD45. (C) Antigenic proﬁle of CDCs by ﬂow cytometry. CDC ¼ cardiosphere-derived cell; DDR2 ¼ discoidin
domain-containing receptor 2; SMA ¼ smooth muscle actin.
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114insertion) occurred after randomization but before CDC
infusion. Two episodes of SAEs occurred in the control
group (in 1 patient): chest pain (n ¼ 1) and a noncardiac
event (hiatal hernia [n ¼ 1]). The only SAE ruled by the
DSMB to be possibly related to the study therapy was
a non–ST-segment elevation MI in 1 CDC-treated patient
occurring 7 months after cell infusion. During serial follow-
up Holter recordings, 8 of 17 (47.1%) CDC-treated patients
and 2 of 8 (25%) controls had at least 1 episode of
ventricular tachycardia (deﬁned as 3 consecutive beats at
a rate 100 beats/min, p ¼ 0.4 between groups). All epi-
sodes were asymptomatic and brief in duration; the ave-
rage duration did not differ signiﬁcantly between groups
(4.0  2.2 beats/min [CDCs] vs. 4.0  1.4 beats/min
[controls], p ¼ 0.655). No episodes of sustained ventricular
tachycardia or ventricular ﬁbrillation were recorded during
follow-up. By 12 months, 6 patients in the CDC group
reported a hospitalization (8 hospitalization events), whereas
1 control patient did so (2 hospitalization events) (p ¼ 0.36).
Two of 8 hospitalizations in the CDC group occurred after
randomization but before CDC infusion. Apart from the
aforementioned non–ST-segment-elevation MI, no events
were noted when considering death, major adverse cardiac
events (composite of death and hospital admission for heartfailure or nonfatal recurrent MI), or tumor formation seen
on MRI (Table 1). With regard to the 2 patients (1 treated
and 1 control) who were lost to follow-up and did not
complete their 1-year visits, we have ascertained from the
Social Security Death Index (33) that both patients were
alive at the 1-year endpoint; however, we have no other
information on them.
Efﬁcacy: functional and quality-of-life assessments. NYHA
functional class did not change signiﬁcantly between base-
line and 1 year in either the treated or the control group
(baseline: NYHA functional class I [12 of 16 vs. 6 of 8],
NYHA functional class II [4 of 16 vs. 1 of 8], NYHA
functional class III [0 of 16 vs. 1 of 8]; 1 year: NYHA
Table 2
Pooled Data of MRI-Measured Parameters in
CDC-Treated and Control Patients
CDCs Controls p Value
Scar mass at baseline, g 26.6  11.5 23.3  5.5 0.482
Scar mass at 1 yr, g 16.2  8.1 21.6  7.1 0.167
D Scar mass, g 11.9  6.8 1.7  7.8 0.008
Scar size at baseline, % LV 23.8  9.9 22.4  7.9 0.768
Scar size at 1 yr, % LV 12.9  6.1 20.3  7.5 0.036
D Scar size, % LV 11.1  4.6 2.2  7.1 0.004
Viable mass at baseline, g 86.9  24.5 85.0  23.8 0.874
Viable mass at 1 yr, g 108.3  24.8 86.8  19.4 0.070
D Viable mass, g 22.6  9.4 1.8  8.7 <0.001
EDV at baseline, ml 169.5  40.1 151.7  34.7 0.338
EDV at 1 yr, ml 156.9  57.3 151.6  47.4 0.838
D EDV, ml 12.7  56.0 0.2  26.1 0.636
ESV at baseline, ml 97.8  34.4 91.4  32.1 0.938
ESV at 1 yr, ml 84.3  43.1 82.5  37.3 0.817
D ESV, ml 13.2  48.1 8.9  18.7 0.913
EF at baseline, % 42.4  8.9 42.5  11.1 0.987
EF at 1 yr, % 48.2  10.3 48.2  11.4 0.997
D EF, % 5.4  10.6 5.8  3.3 0.636
Stroke volume at
baseline, ml
71.7  19.2 60.3  9.9 0.162
Stroke volume at 1 yr, ml 72.6  23.9 69.1  18.2 0.757
D Stroke volume, ml 0.5  10.1 8.8  9.9 0.090
Cardiac output at
baseline, l/min
4.7  1.4 4.0  0.8 0.261
Cardiac output at 1 yr, l/min 4.4  1.3 4.4  1.2 0.926
D Cardiac output, l/min 0.4  1.3 0.4  0.6 0.194
Left ventricular mass at
baseline, g
114.9  24.7 108.2  24.1 0.567
Left ventricular mass at
1 yr, g
121.3  25.5 108.3  19.9 0.260
D Left ventricular mass, g 6.5  13.5 0.1  7.4 0.079
Values are mean  SD.
CDC ¼ cardiosphere-derived cell; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; ESV ¼ end-
systolic volume; LV ¼ left ventricle; MRI ¼ magnetic resonance imaging.
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115functional class I [14 of 16 vs. 6 of 7], NYHA functional
class II [2 of 16 vs. 1 of 7], NYHA functional class III [0 of
16 vs. 0 of 7] in the treated and control groups, respec-
tively). At 1 year, peak VO2 remained unchanged in both
the treated (baseline: 29.2  5.2 ml/kg/min, 1 year: 31.4 
6.9 ml/kg/min; p ¼ 0.121) and control groups (baseline:
33.1  6.2 ml/kg/min, 1 year: 37.2  4.7 ml/kg/min; p ¼
0.192). No change was observed in the total Minnesota
Living With Heart Failure Questionnaire score in either the
treated (baseline: 21.9  14.9, 1 year: 20.5  20.8; p ¼
0.649) or the control group (baseline: 32.7  24.8, 1 year:
20.7  21.0; p ¼ 0.100). Patients who received CDCs
showed a trend toward an increase in distance walked in 6
min at 1 year (461.1  128.5 m) compared with baseline
(baseline: 433.2  115.4; p ¼ 0.086) that was not observed
in control patients (baseline: 439.3  75.2m, 1 year:
429.7  61.3 m; p ¼ 0.786).
Efﬁcacy: cardiac MRI. We used cardiac MRI to look for
potential indicators of regenerative or functional efﬁcacy.
The pooled data of MRI-measured parameters are presentedin Table 2, and a complete list of all MRI-measured
parameters for each patient is provided in Online Table 2.
The pooled absolute changes in scar size (scar mass
normalized by total LV mass) from baseline to 1 year are
presented in Figure 2A. Scar size remained unchanged in
controls (D ¼ 2.2  7.1%, p ¼ 0.452 within group) but
decreased in CDC-treated patients (D: 11.1  4.6%,
p < 0.001 within group, p ¼ 0.004 between groups) over the
period of 1 year (Fig. 2A, Online Fig. 1A). The absolute
decrease in scar size observed in CDC-treated patients
amounted to a 45.4% ( 12.5%) relative decrease in scar size
and resulted in signiﬁcantly smaller scar size in CDC-
treated patients (12.9  6.1%) compared with controls
(20.3  7.5%, p ¼ 0.036 between groups) 1 year after cell
infusion.
Cardiac MRI can quantify independently scar mass and
viable mass (the 2 variables that determine scar size). Both
scar mass (D ¼ 1.7  7.8 g, p ¼ 0.588 within group) and
viable mass (D ¼ þ1.8  8.7 g, p ¼ 0.605 within group)
remained virtually unchanged in control patients over 1 year.
In contrast, CDC-treated patients exhibited sizable de-
creases in scar mass (11.9 6.8 g, p < 0.001 within group,
p ¼ 0.008 between groups ) and increases in viable mass
(þ22.6  9.4 g, p < 0.001 within group, p < 0.001 between
groups) over the period of 1 year after cell infusion (Fig. 2B,
Online Figs. 1B and 1C). Importantly, the observed
reductions in scar mass correlated with the increments in
viable myocardium, consistent with a therapeutic response in
which scar is replaced by viable myocardium (Fig. 2C,
Online Fig. 1D).
Online Figure 2 shows the MRI measurements of scar
size, scar mass, and viable mass in the single patient who was
infused with CDCs 14 months post-MI. This patient
responded in a manner qualitatively similar to that of
patients treated 1.5 to 3 months post-MI: scar size decreased
by 7.2%, scar mass decreased by 5.8 g, and viable mass
increased by 14.3 g over the year after CDC infusion; the
aforementioned parameters had not improved spontaneously
during the ﬁrst 14 months post-MI.
Regional function was assessed in infarcted myocardial
segments (deﬁned as segments containing scar at baseline),
after visual identiﬁcation of such segments in corresponding
delayed contrast-enhanced images. At baseline, regional
function of infarcted segments (as measured by mid-wall
Ecc, systolic thickening, and end-systolic thickness) was
similar between groups. At 1 year, CDC-treated infarcted
myocardial segments displayed improved (more negative)
mid-wall Ecc (12.7  5.9% vs. 10.0  4.5%, p ¼ 0.020
between groups), increased systolic thickening (35.9 
31.8% vs. 28.4  22.4%, p ¼ 0.008 between groups), and
increased end-systolic thickness (10.3  3.2 mm vs. 9.4 
3.7 mm, p¼ 0.004 between groups) compared with infarcted
segments of control patients (Figs. 2D to 2F).
To determine whether the improvement in regional
function correlates with the increase in regional tissue
viability, we matched delayed contrast-enhanced images and
Figure 2
Autologous CDCs Decrease Scar Size, Decrease Scar Mass, Increase Viable Myocardium, and Improve Regional Function
of Infarcted Myocardium
(A) Changes in scar size from baseline to 1 year. (B) Changes in scar mass and viable mass from baseline 1 year. (C) Correlation between the change in scar mass and the
change in viable mass in individual control and CDC-treated subjects from baseline to 1 year (blue line of best ﬁt is derived only from the CDC-treated patients). (D) Regional
strain in infarcted segments at 1 year in control patients and CDC-treated patients. (E) Systolic thickening in infarcted segments at 1 year in control and CDC-treated patients.
(F) End-systolic thickness in infarcted segments at 1 year in controls and CDC-treated subjects. *p < 0.05 compared to controls. CDC ¼ cardiosphere-derived cell; Ecc ¼
systolic circumferential strain; ES ¼ end-systolic.
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(baseline and 1 year) and investigated whether changes in
the percentage of infarcted tissue correlate (inversely) with
changes in regional systolic function (measured by systolic
thickening). Figure 3A shows representative examples of this
analysis. At baseline, the delayed contrast-enhanced images
in both patients show an anteroseptal scar (of approximately
the same size, pseudocolored in pink as determined by the
semiautomated FWHM analysis) that is accompanied by
a similar degree of hypokinesia in the infarcted myocardial
segments. One year later, in the control patient, there are nomajor changes in scar mass, viable myocardial mass, or
regional systolic function. In contrast, in the treated patient,
the scar decreased in both circumference and transmurality,
whereas viable myocardial mass increased 1 year after CDC
infusion. The treated infarcted segments (highlighted by
arrows) showed a recovery of systolic function over the period
of 1 year (Fig. 3A; see also Online Videos 1, 2, 3, and 4).
Figure 3B shows scatterplots of the changes in the
percentage of infarcted tissue and the changes in systolic
thickening for every infarcted segment of treated and control
patients. The infarcted segments of the control patients on
Figure 3 Comprehensive Magnetic Resonance Imaging Analysis of Regeneration
(A) Representative matched, delayed contrast-enhanced magnetic resonance images and their corresponding cine short-axis images (at end-diastole [ED] and end-systole [ES])
at baseline and 1 year (see Online Videos 1, 2, 3, and 4). In the pseudocolored, delayed contrast-enhanced images, infarct scar tissue, as determined by the full width half
maximum method, appears pink. Each cardiac slice was divided into 6 segments (using the right ventricle insertion as a reference point). Infarcted segments were visually
identiﬁed from delayed contrast-enhanced images. Scar size (percentage of infarcted tissue per segment) and systolic thickening were calculated for each individual infarcted
segment at baseline and 1 year. Endocardial (red) and epicardial (green) contours of the left ventricle are shown. In the CDC-treated patient (top row), scar decreased, viable
mass increased and regional systolic function improved over the period of 1 year in the treated infarcted segments (highlighted by arrows). In contrast, no major changes in
scar mass, viable myocardial mass, or regional systolic function were observed in the control patient (bottom row). (B) Scatterplots of the changes in the percentage of
infarcted tissue and the changes in systolic thickening for every infarcted segment of treated and control patients. ED ¼ end-diastole; other abbreviations as in Figures 1 and 2.
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infarcted tissue or systolic thickening over time; no corre-
lation was evident between the 2 parameters (p ¼ 0.277). In
contrast, a substantial portion of the CDC-treated infarcted
segments showed a decrease in the percentage of scar tissue
coupled with an improvement of systolic thickening over 1
year. The decrease in the percentage of infarcted tissue
correlated strongly with the improvement in systolic func-
tion (r ¼ 0.596, p < 0.001).
In terms of global LV function, no differences in the
change of LVEF from baseline to 1 year were observed
between CDC-treated patients (5.4  10.6%) and control
patients (5.8  3.3%, p ¼ 0.636 between groups). Toinvestigate whether the changes in LVEF in CDC-treated
patients are consistent with the observed reductions in scar
size and whether the changes in control subjects fall within
the range of expected variability, we examined the natural
relationship between scar size and EF in convalescent MI
independent of cell therapy. As previously described (22), 90
patients underwent cardiac MRI post-MI for measurement
of EF and scar size. The previously unpublished results
at w5 months post-MI (a time at which scar size has
stabilized) are depicted in the scatterplot in Figure 4. When
the mean values for scar size and EF in CADUCEUS
patients are superimposed onto the scatterplot, it becomes
evident that the changes in LVEF in CDC-treated patients
Figure 4 Global Function and Left Ventricular Volumes
(A) Scatterplot showing the natural relationship between scar size and left
ventricular ejection fraction w5 months post-myocardial infarction (circles). Each
cross symbol represents the mean values (at the intersection of the vertical and
horizontal bars [obtained from all patients with magnetic resonance imaging
measurements]), whereas the width of each bar equals SEM of scar size and left
ventricular ejection fraction of CADUCEUS patients at baseline, 6 months, and 1
year; the crosses are superimposed onto the scatterplot showing prior data from
post-myocardial infarction patients with variable scar sizes. The changes in left
ventricular ejection fraction in CDC-treated subjects are consistent with the natural
relationship between scar size and ejection fraction in convalescent myocardial
infarction, whereas the changes in left ventricular ejection fraction in controls fall
within the margins of variability. (B) Changes in end-diastolic volume from baseline
to 1 year. (C) Changes in end-systolic volume from baseline to 1 year. CDCs ¼
cardiosphere-derived cells; EDV ¼ end-diastolic volume; EF ¼ ejection fraction;
ESV ¼ end-systolic volume; LV ¼ left ventricle.
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and EF in convalescent MI, whereas the changes in LVEF
in control patients fall within the margins of variability
(Fig. 4A, Online Fig. 3). With regard to cardiac volumes, no
differences in the change of end-diastolic (Fig. 4B) and end-
systolic (Fig. 4C) volumes from baseline to 1 year were seen
in CDC-treated patients (DEDV ¼ 12.7  56.0 ml and
DESV ¼ 13.2  48.1 ml) compared with controls
(DEDV ¼ 0.2  26.1 ml and DESV ¼ 8.9  18.7 ml,
p ¼ 0.636 and p ¼ 0.913, respectively) at 1 year. No
differences in the change of cardiac output or stroke volume
from baseline to 1 year were detected in treated patients
compared with control patients (Table 2).
Predictors of efﬁcacy. We performed covariate analysis
to investigate predictors of regenerative efﬁcacy in CDC-
treated patients at 1 year. Higher baseline scar size was
strongly associated with greater scar size reduction 1 year
after cell infusion (r ¼ 0.890, p < 0.001) (Fig. 5A,
Online Fig. 4A). A weak correlation between scar size
reduction and baseline EF was observed (r ¼ 0.588, p ¼
0.044) (Fig. 5B, Online Fig. 4B). However, when multiple
linear regression analysis (using scar size treatment effect as
the dependent variable and baseline EF and baseline scar
size as independent variables) was performed, only baseline
scar size (p ¼ 0.002), but not baseline EF (p ¼ 0.868), was
associated with regenerative efﬁcacy. Scar size treatment
effect did not correlate with the time from MI to CDC
infusion (Fig. 5C, Online Fig. 4C). Scar size reduction was
similar in patients with a history of a temporally remote MI
(12.0  4.4%) and patients without a previous MI
(10.6  4.9%, p ¼ 0.649 between groups) (Fig. 5D,
Online Fig. 4D).
Discussion
The ultimate goal of cell therapy is to achieve myocardial
regeneration. From the ﬁrst principles, genuine regeneration
should be manifested by regrowth of new functional heart
muscle. Despite more than a decade of clinical trials of cell
therapy, this goal remains largely elusive. In the 6-month
data from the prospective, randomized, controlled CADU-
CEUS trial (10), we demonstrated that intracoronary infu-
sion of autologous CDCs post-MI is feasible and appears to
be safe and effective in decreasing scar size and increasing
viable myocardium. The present study investigated the
longevity of these effects at 1 year after cell administration;
the results were only partially available at the time of the
initial report.
Final 1-year data from CADUCEUS show that intra-
coronary administration of autologous CDCs in patients
with convalescent MI did not raise signiﬁcant safety
concerns. The frequency of mild TnI increases (2 of 17) after
CDC infusion falls within the range associated with elective
angioplasty (5% to 30%) (34). Because there was no placebo
control group, we cannot assess with certainty whether the
cells were culpable or whether the mild TnI elevations were
Figure 5 Predictors of Efﬁcacy
(A) Correlation between the change in scar size (from baseline to 1 year) and baseline scar size. (B) Correlation between the change in scar size (from baseline to 1 year) and
baseline left ventricular ejection fraction. (C) Correlation between the change in scar size (from baseline to 1 year) and time from MI to infusion of CDCs. (D) Changes in scar
size from baseline to in year in CDC-treated patients with and without history of temporally remote myocardial infarction (MI). Abbreviations as in Figures 1 and 4.
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be acknowledged that numerically higher rates of non-
sustained ventricular tachycardias and SAEs were recorded
in CDC-treated patients; the frequency of adverse events
should be examined further in future trials.
Although the primary endpoints of the study were safety-
related, we observed intriguing hints of efﬁcacy. Autologous
CDCs decreased scar size and improved regional function of
infarcted myocardium (both were pre-speciﬁed exploratory
secondary efﬁcacy endpoints). Importantly, the correlation
of scar shrinkage with the increase in viability and im-
provement in regional function is consistent with genuine
therapeutic regeneration.
Despite the improvements in scar size and regional
function, no improvements in global function were detected.
Although the changes in LVEF in CDC-treated subjects
were consistent with the natural relationship between scar
size and EF in convalescent MI, we also observed an
increase in LVEF in control patients (without any signiﬁ-
cant changes in scar measures) that falls within the marginsof variability. Given the multiplicity of factors that inﬂuence
EF (but not scar size, which is a structural parameter [35])
and the much higher precision of MRI for measuring scar
size compared with EF (21,36), we expect that larger studies
will be required to ascertain genuine changes in global
function in CDC-treated patients (and in control patients).
In addition, we did not detect any improvements in NYHA
functional class, peak VO2, distance walked in 6 min or
quality of life after therapy with CDCs. However, our
relatively small study provided a low statistical power envi-
ronment, where comparisons between groups are often
uninformative and the absence of evidence does not neces-
sarily translate to evidence of absence. Ultimately, appro-
priately powered studies are required to assess functional
efﬁcacy of CDCs.
CADUCEUS is the ﬁrst and only controlled study to
show an increase in viable myocardium, a prerequisite for
myocardial regeneration. A recent interim analysis of an
ongoing phase 1, single-center clinical trial using c-Kitþ
heart-derived cells (28) in surgically revascularized patients
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120also showed an increase in viable myocardium after cell
administration (37); however, the conclusions may be
undermined by methodological concerns (38).
Although cardiac MRI has been extensively validated and
is considered the gold-standard imaging modality for the
quantiﬁcation of scarred and viable myocardium (21,39), it
cannot distinguish cardiac hypertrophy from hyperplasia.
However, histology data from pre-clinical studies rule out
myocyte hypertrophy as a contributor to the increase in
viable myocardium observed after CDC therapy and suggest
instead that the increased viable myocardium in the CDC-
treated hearts is a direct result of an increased number of
myocytes (10,40).
Important unresolved issues in the ﬁeld of cell therapy
include the identiﬁcation of the patient population that will
beneﬁt most from cell transplantation and the ideal time of
cell administration post-MI (41). With regard to the former,
we show that higher baseline scar size was associated with
greater regenerative efﬁcacy in treated patients. This ﬁnding
is in agreement with previous studies: in the BOOST
(BOne marrOw transfer to enhance ST-elevation infarct
regeneration) trial, sustained functional improvement was
observed only in patients with greater infarct transmurality
(5), and in the study by Janssens et al. (3), bone marrow
mononuclear cell administration led to enhanced recovery of
regional function only in the most severely infarcted
myocardial segments. Similar conclusions have been reached
in subgroup analyses of the REPAIR-AMI (Reinfusion of
Enriched Progenitor Cells and Infarct Remodeling in Acute
Myocardial Infarction) (6) and REGENT (Myocardial
Regeneration by Intracoronary Infusion of Selected Pop-
ulation of Stem Cells in Acute Myocardial Infarction) (42)
trials. These ﬁndings suggest that the greatest beneﬁts of
cell therapy occur in patients with the greatest infarct-
induced myocardial damage, a realization that should
inform the design of future clinical trials. It is equally
possible, however, that subtle changes may be more difﬁcult
to quantify in patients with smaller baseline scars. With
regard to the optimal time of cell administration, regenera-
tive efﬁcacy of CDCs in the CADUCEUS trial did not
correlate with time from MI to infusion or history of
temporally remote MI. In addition, the single patient
infused off-protocol 14 months post-MI responded similarly
to patients infused at 1.5 to 3 months post-MI. These
results suggest that CDCs may confer similar beneﬁts in
chronic ischemic cardiomyopathy, as in convalescent MI.
The CADUCEUS trial was not designed to offer
mechanistic insights into how CDCs may regenerate the
infarcted heart. Even though CDCs are multipotent and
clonogenic, and thus satisfy conventional criteria for cardiac
progenitors (43), extensive pre-clinical evidence supports the
conclusion that the mechanism of beneﬁt is indirect (24,44).
Cardiospheres and CDCs decrease scar mass by exerting
ﬁbrolytic actions (45) and increase viable myocardium
through recruitment of endogenous progenitors and induc-
tion of resident cardiomyocyte proliferation in the infarctborder zone (40). The indirect mechanisms of action (which
share similarities with growth factor–based approaches
[46–48]) rely on activation of endogenous reparative and
regenerative pathways rather than long-term engraftment
and differentiation of transplanted cells; thus, the “stemness”
of CDCs appears to be unrelated to their efﬁcacy. If, indeed,
long-term survival of transplanted cells is not required for
regenerative efﬁcacy, then allogeneic CDCs may work
without immunosuppression. In agreement with this
prediction, we have shown that allogeneic cardiospheres and
their progeny are just as effective as syngeneic CDCs in a rat
model of MI (24,45). In addition, the POSEIDON
(Percutaneous Stem Cell Injection Delivery Effects on
Neomyogenesis Pilot Study) study of bone marrow mesen-
chymal cells showed that therapy with allogeneic cells
appears to be safe and at least as active as therapy with
autologous mesenchymal cells (49). The safety and efﬁcacy
of allogeneic CDCs in human subjects with LV dysfunction
post-MI are currently being tested in the phase 1/2
randomized, double-blind, placebo-controlled ALLSTAR
trial (ALLogeneic heart STem cells to achieve myocArdial
Regeneration) (50). This study not only examines allogeneic
cells, but also expands the eligibility window to as long as
1 year post-MI; the results will help settle the question of
whether time from index MI is a major determinant of
efﬁcacy.
Study limitations. First, 2 patients (1 treated and 1
control) were lost to follow-up and did not complete their 1
year visits. Although both subjects were alive at the 1-year
endpoint, we have no other information with regard to
possible adverse events occurring between 6 months and 1
year, or their functional status at 1 year. Second, even though
we did observe intriguing hints of regenerative efﬁcacy in our
study, it should be emphasized that CADUCEUS was
a small phase 1 study, not powered to assess efﬁcacy in
a deﬁnitive manner; thus, the encouraging indications of
bioactivity merit further investigation in future trials.
Conclusions
We ﬁnd that intracoronary administration of autologous
CDCs did not raise statistically signiﬁcant safety concerns.
Analysis of exploratory efﬁcacy endpoints revealed a decrease
in scar size, an increase in viable myocardium, and improved
regional function of infarcted myocardium 1 year post-
treatment. These ﬁndings motivate the further exploration
of CDCs in future clinical studies.Acknowledgments
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